Simple Blood Test can Detect Prostate Cancer with High Accuracy

by Iswarya on  September 11, 2019 at 1:11 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

Prostate cancer can be identified efficiently and accurately with the help of a simple blood test along with the current prostate-specific antigen (PSA) test, according to a new study. This will help to avoid unnecessary invasive biopsies, over-diagnosis, and over-treatment. The findings of the study are published in the Journal of Urology.
Simple Blood Test can Detect Prostate Cancer with High Accuracy
Simple Blood Test can Detect Prostate Cancer with High Accuracy

Prostate cancer is the most common cancer in Western men, with 1.3 million new cases being diagnosed each year worldwide. It is currently detected using a blood test that measures PSA levels. Although it provides early diagnosis, the PSA blood test has low specificity (high false positives) with about 75 percent of all PSA positive results ending up with negative biopsies that do not find cancer.

Show Full Article


When a high PSA level in the blood is detected, the patient undergoes a tissue biopsy of the prostate gland, which is invasive and carries a significant risk of bleeding and infection. On biopsy, the majority of patients with elevated PSA levels are found not to have cancer.

Additionally, most diagnosed early-stage prostate cancers are not fatal if left untreated. The current practice of the combined PSA test and biopsy for prostate cancer, therefore, results in unnecessary biopsies and over-diagnosis and overtreatment of many men.

The new prostate cancer test (the Parsortix® system from ANGLE plc) detects early cancer cells or circulating tumor cells (CTCs) that have left the original tumor and entered the bloodstream prior to spreading around the body. By measuring intact living cancer cells in the patient's blood, rather than the PSA protein which may be present in the blood for reasons other than cancer, it potentially provides a more accurate test for prostate cancer.

The study, published in the Journal of Urology, looked at the use of the CTC test in 98 pre-biopsy patients and 155 newly diagnosed prostate cancer patients enrolled at St Bartholomew's Hospital in London. The research team found that the presence of CTCs in pre-biopsy blood samples were indicative of the presence of aggressive prostate cancer, and efficiently and non-invasively predicted the later outcome of biopsy results.

When the CTC tests were used in combination with the current PSA test, it was able to predict the presence of aggressive prostate cancer in subsequent biopsies with over 90 percent accuracy, better than any previously reported biomarkers.

Additionally, the number and type of CTCs present in the blood were also indicative of the aggressiveness of cancer. Focusing on more aggressive prostate cancer may reduce overtreatment and unnecessary biopsies for benign and non-aggressive conditions.

Lead researcher Professor Yong-Jie Lu from the Queen Mary University of London said: "The current prostate cancer test often leads to unnecessary invasive biopsies and over-diagnosis and overtreatment of many men, causing significant harm to patients and a waste of valuable healthcare resources. There is clearly a need for a better selection of patients to undergo the biopsy procedure.

"Testing for circulating tumor cells is efficient, non-invasive, and potentially accurate, and we've now demonstrated its potential to improve the current standard of care. By combining the new CTC analysis with the current PSA test, we were able to detect prostate cancer with the highest level of accuracy ever seen in any biomarker test, which could spare many patients unnecessary biopsies. This could lead to a paradigm shift in the way we diagnose prostate cancer."

As this is a single-center study, the results need to be further validated in other independent research centers before the CTC test is available either privately or on the NHS in the UK, which could take a further 3-5 years. Clearance by the US Food and Drug Administration could also take 3-5 years.

This work was funded by Orchid Cancer Appeal, Cancer Research UK, and ANGLE plc (which manufactures the Parsortix system). The funding sources had no role in the design of the study; the collection, analysis, or interpretation of the data; or the writing of the research paper.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive